Mind Medicine (Mind Med) Inc. MNMD
We take great care to ensure that the data presented and summarized in this overview for Mind Medicine (MindMed) Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in MNMD
Top Purchases
Top Sells
About MNMD
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
Insider Transactions at MNMD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 25
2025
|
Carrie Liao Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,347
-1.59%
|
$14,082
$6.74 P/Share
|
|
Mar 25
2025
|
Mark Sullivan Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
6,576
-2.03%
|
$39,456
$6.74 P/Share
|
|
Mar 25
2025
|
Dan Karlin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,836
-1.51%
|
$41,016
$6.74 P/Share
|
|
Mar 25
2025
|
Robert Barrow Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
21,208
-2.42%
|
$127,248
$6.74 P/Share
|
|
Mar 12
2025
|
Carrie Liao Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+26.01%
|
-
|
|
Mar 12
2025
|
Mark Sullivan Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+31.7%
|
-
|
|
Mar 12
2025
|
Dan Karlin Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
115,000
+20.25%
|
-
|
|
Mar 12
2025
|
Robert Barrow Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
350,000
+28.51%
|
-
|
|
Dec 26
2024
|
Mark Sullivan Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,519
-2.54%
|
$31,633
$7.43 P/Share
|
|
Dec 26
2024
|
Dan Karlin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,643
-1.93%
|
$46,501
$7.43 P/Share
|
|
Dec 26
2024
|
Carrie Liao Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,273
-2.28%
|
$15,911
$7.43 P/Share
|
|
Dec 26
2024
|
Robert Barrow Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
19,106
-3.5%
|
$133,742
$7.43 P/Share
|
|
Dec 05
2024
|
David W Gryska |
BUY
Open market or private purchase
|
Direct |
2,500
+11.19%
|
$17,500
$7.17 P/Share
|
|
Sep 25
2024
|
Robert Barrow Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
19,771
-3.5%
|
$98,855
$5.98 P/Share
|
|
Sep 25
2024
|
Carrie Liao Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,352
-2.31%
|
$11,760
$5.98 P/Share
|
|
Sep 25
2024
|
Mark Sullivan Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,430
-2.43%
|
$22,150
$5.98 P/Share
|
|
Sep 25
2024
|
Dan Karlin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,871
-1.95%
|
$34,355
$5.98 P/Share
|
|
Aug 23
2024
|
David W Gryska |
BUY
Open market or private purchase
|
Direct |
3,500
+16.79%
|
$17,500
$5.98 P/Share
|
|
Aug 21
2024
|
Miri Halperin Wernli Executive President |
SELL
Payment of exercise price or tax liability
|
Direct |
32,595
-13.87%
|
$195,570
$6.17 P/Share
|
|
Aug 21
2024
|
Miri Halperin Wernli Executive President |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+17.54%
|
$150,000
$3.7 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 665K shares |
|---|---|
| Open market or private purchase | 7K shares |
| Exercise of conversion of derivative security | 50K shares |
| Open market or private sale | 143K shares |
|---|---|
| Payment of exercise price or tax liability | 32.6K shares |